Highlights and Quick Summary
- SG&A Expenses for the quarter ending December 31, 2022 was $1.86 Million (a -2.97% decrease compared to previous quarter)
- Year-over-year quarterly SG&A Expenses increased by 39.34%
- Annual SG&A Expenses for 2022 was $6.65 Million (a 2.06% increase from previous year)
- Annual SG&A Expenses for 2021 was $6.51 Million (a 6.96% increase from previous year)
- Annual SG&A Expenses for 2021 was $6.09 Million (a 9.36% increase from previous year)
- Twelve month SG&A Expenses ending December 31, 2022 was $6.67 Million (a 2.28% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses increased by 0.68% year-over-year
Trailing SG&A Expenses for the last four month:
31 Dec '22 | 30 Sep '22 | 30 Jun '22 | 31 Mar '22 |
---|---|---|---|
$6.67 Million | $6.52 Million | $6.65 Million | $6.63 Million |
Visit stockrow.com/BNTC
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of Benitec Biopharma Limited
Most recent SG&A Expensesof BNTC including historical data for past 10 years.Interactive Chart of SG&A Expenses of Benitec Biopharma Limited
Benitec Biopharma Limited SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $1.86 | $1.92 | $1.55 | $1.34 | $6.65 |
2021 | $1.71 | $2.04 | $1.54 | $1.03 | $6.51 |
2020 | $2.11 | $1.84 | $1.64 | $1.29 | $5.57 |
2019 | – | – | $1.84 | $0.75 | $4.61 |
2018 | – | – | – | – | $2.0 |
2017 | – | – | – | $0.55 | $2.19 |
2016 | – | – | – | $0.43 | $2.9 |
2015 | – | – | – | – | $2.85 |
2014 | – | – | – | – | $1.52 |
2013 | – | – | – | – | $1.42 |
Business Profile of Benitec Biopharma Limited
Sector: Healthcare
Industry: Biotechnology